Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera.
about
Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerationsJAK and MPL mutations in myeloid malignancies.JAK2 V617F detected in two B-cell chronic lymphocytic leukemia patients without coexisting Philadelphia chromosome-negative myeloproliferative neoplasms: A report of two cases.Differential sensitivity to JAK inhibitory drugs by isogenic human erythroblasts and hematopoietic progenitors generated from patient-specific induced pluripotent stem cellsTreatment with the Bcl-xL inhibitor ABT-737 in combination with interferon α specifically targets JAK2V617F-positive polycythemia vera hematopoietic progenitor cellsSimultaneous and sequential concurrent myeloproliferative and lymphoproliferative neoplasms.Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells.Interferon-alpha targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway.Correction of the abnormal trafficking of primary myelofibrosis CD34+ cells by treatment with chromatin-modifying agentsThe orally bioavailable MDM2 antagonist RG7112 and pegylated interferon α 2a target JAK2V617F-positive progenitor and stem cells.Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer.Torque teno virus 10 isolated by genome amplification techniques from a patient with concomitant chronic lymphocytic leukemia and polycythemia vera.Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis.In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2 V617F allele.Lipocalin produced by myelofibrosis cells affects the fate of both hematopoietic and marrow microenvironmental cells.Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera.Proinflammatory Cytokine IL-6 and JAK-STAT Signaling Pathway in Myeloproliferative Neoplasms.Molecular approach to diagnose BCR/ABL negative chronic myeloproliferative neoplasms.Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-α 2a specifically targets JAK2V617F-positive polycythemia vera cellsSpleens of myelofibrosis patients contain malignant hematopoietic stem cellsComparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disordersJAK2V617F-negative ET patients do not display constitutively active JAK/STAT signaling.Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia veraHistological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers.Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens.Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM090Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms.Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond.Hematopoietic stem cells, progenitor cells and leukemic stem cells in adult myeloproliferative neoplasms.Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance.Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia.Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs).Targeting glutamine metabolism in myeloproliferative neoplasms.Myeloproliferative neoplasm stem cells.Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells.Involvement of mast cells by the malignant process in patients with Philadelphia chromosome negative myeloproliferative neoplasms.Chronic lymphocytic leukemia presenting as an intracranial epidural mass in a patient with myeloproliferative neoplasm associated with JAK2 V617F mutation.T cells from patients with polycythemia vera elaborate growth factors which contribute to endogenous erythroid and megakaryocyte colony formation.
P2860
Q28078404-3F254E1A-F572-476F-9D98-B479A17574C1Q33378737-30D4A7FD-7BE6-40AE-8C30-5670B787C2C8Q33843882-3942CA77-1829-45A8-B720-29641E2A0205Q33894805-C7BC9CDE-5B3C-46C6-A1E1-95A0F192DDBBQ34360366-F2686326-7C52-4C80-A09B-39D0EA1A7013Q34519513-6DDE98FC-8EE6-48A8-9C2C-21ACEDE51A73Q34541582-0406C7D2-E77F-499D-AB39-2C75AB580B01Q34949540-401776A1-4EC6-47EC-9881-4E065E566661Q35603419-4E076FFD-80A1-430C-902D-E2CAC45F974CQ35743852-65797432-9CA7-41EA-BBAB-D4CDD52340EFQ35858979-BE112907-6E76-49E7-B8B6-5899F55E2E8DQ35876861-B6E21A3C-8E51-4F3C-BEAF-E48DBDFECDC2Q35901696-ABED389C-0337-40E3-9404-A8957283CF7CQ35910887-37182036-62FA-470B-A8C6-E340C540CAFEQ35976594-A25A8040-DCA2-4B3F-AC58-FD644C5ED5D0Q36079782-D03481B5-1191-4CEC-87BA-5C38BEAF0EF0Q36150377-7117488E-7FA7-4625-BA11-E60E11BED7E9Q36153557-09A230BF-7C42-49B0-866D-246DA09704ADQ36318162-F721DEC9-0AED-4EE7-A637-C3AC844BEC4AQ36356466-BFC8E9D9-1840-4C08-910C-F3C90E69F5E8Q36374813-B55D79AC-2995-470B-91B8-4E6AC5EA8011Q36501857-E473A983-C335-470D-91DB-B377EEC9C403Q36814639-65369A9C-BC0C-4548-B4A2-030D69A1B7D7Q36857941-1B9B7D19-3160-499C-A284-ABFC2C93DDF8Q37009717-B1614B6E-0055-4004-945C-7C2B7A54C490Q37170349-134AF708-63C6-4460-9FD2-5181CC639FE2Q37250169-84C4C496-6DD1-44FF-851A-8AE65DB1B8A2Q37379320-EDEE885C-6CF1-422E-9FD0-4D983E83F62AQ37810100-98C20499-0B56-46FB-BF5F-A34C1C641412Q37833893-5CE38056-CEC6-4B35-8984-D74D82BDFF21Q38046648-85F8A09C-CB1B-44A3-92B5-C1A7246122BBQ38081267-F8DE090C-76F4-475B-A31C-6D2F0D46EB72Q38087202-FDF47306-DBED-402B-835F-E8319009112FQ38699339-AF4F0503-8699-434D-B3D8-A52F0D05ECD4Q38847693-656F5B8E-ABF2-4CE8-8347-42DCA54B8FDDQ39118859-CA38790B-F99F-4B6D-9BE6-F08496E5B7F2Q42133453-B98388C3-8649-4C76-A0B1-D651EB7876DAQ46040082-9E7656EA-AD78-4164-9CFB-3BFAA9BC525DQ48326539-BB9CC0CB-2EB6-49C2-A8D7-2CBEBB2CBFA7Q50929723-83ED7F7E-59E7-4BF2-9C58-7E05EF2DE3D9
P2860
Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Involvement of various hematop ...... mutation in polycythemia vera.
@en
Involvement of various hematop ...... mutation in polycythemia vera.
@nl
type
label
Involvement of various hematop ...... mutation in polycythemia vera.
@en
Involvement of various hematop ...... mutation in polycythemia vera.
@nl
prefLabel
Involvement of various hematop ...... mutation in polycythemia vera.
@en
Involvement of various hematop ...... mutation in polycythemia vera.
@nl
P2093
P1433
P1476
Involvement of various hematop ...... mutation in polycythemia vera.
@en
P2093
Edward Bruno
Mingjiang Xu
Ronald Hoffman
Takefumi Ishii
P304
P356
10.1182/BLOOD-2006-04-017392
P407
P577
2006-06-06T00:00:00Z